Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles
Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
